Global Cushing's Syndrome Therapeutics Market 2015-2019

クッシング症候群(Cushing’s Syndrome)治療薬の世界市場:コルチコイド受容体拮抗薬、ソマトスタチン類縁体、コルチゾール合成阻害剤

◆タイトル:Global Cushing's Syndrome Therapeutics Market 2015-2019
◆商品コード:IRTNTR4695
◆調査・発行会社:Technavio (Infiniti Research Ltd.)
◆発行日:2014年11月12日
◆ページ数:69
◆資料形式:pdf / 英語
◆納品方法:Eメール
◆調査対象地域:グローバル
◆産業分野:製薬
◆販売価格オプション(消費税別)
Single UserUSD2,500 ⇒換算¥275,000見積依頼/購入/質問フォーム
Five UserUSD2,800 ⇒換算¥308,000見積依頼/購入/質問フォーム
Enterprise License(社内共有可)USD3,500 ⇒換算¥385,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※商品の納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。(振込先:三菱東京UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社)
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※ご購入後、資料に記載の英語表現や単語の意味に関しましては無料でお答えいたします。(但し、対応範囲は弊社で判断)
※弊社H&Iグローバルリサーチ株式会社はTechnavio (Infiniti Research Ltd.)の日本における正規販売代理店です。

【資料の概要】

当調査レポートでは、クッシング症候群(Cushing's Syndrome)治療薬の世界市場について調査・分析し、エグゼクティブサマリー、市場概観、業界の構造分析、クッシング症候群(Cushing's Syndrome)治療薬の世界市場規模及び予測、市場シェア、地域別分析、購買基準、市場成長要因、市場の課題、市場動向、競争状況、主要企業(ベンダー)分析などの情報をお届けいたします。

About Cushing’s Syndrome
Cushing’s syndrome is a condition caused by the prolonged exposure to very high levels of cortisol. This can occur because of the consumption of glucocorticoid drugs or diseases that result in excess cortisol, ACTH, and CRH secretion. Harvey Cushing described the pathophysiology of this condition in 1932. It is more common in women than in men. Cushing’s syndrome is also known as hypercortisolism, hypercorticism, hyperadrenocorticism, or Itsenko-Cushing syndrome. Some of the common symptoms of Cushing’s syndrome are increase in weight, facial acne, cognitive disorders, and vulnerability to superficial fungus infections, growth of a mass around the collarbone or back of the neck, commonly known as the “buffalo hump,” and puffy face or “moon face”. Other symptoms include sweating, polyuria, and hypertension, dilation of the capillaries, thinning of the skin, red striae, osteoporosis, diabetes mellitus, immune suppression, sleep disturbances, muscle weakness, hirsutism, baldness, and hypocalcemia. Cushing’s syndrome can broadly be classified into corticotropin-dependent Cushing’s syndrome and corticotropin-independent Cushing’s syndrome.

TechNavio’s analysts forecast the Global Cushing’s Syndrome Therapeutics market to grow at a CAGR of 9.41 percent over the period 2014-2019.

[Covered in this Report]
This report covers the present scenario and the growth prospects of the Global Cushing’s Syndrome Therapeutics market for the period 2014-2019. To calculate the market size, the report considers the revenue generated from the sales of various generic, off-label, and branded therapies used in the treatment of Cushing’s syndrome caused in humans.
The report also presents the vendor landscape and a corresponding detailed analysis of the top vendors in the Global Cushing’s Syndrome Therapeutics market. In addition, the report discusses the major drivers that influence the growth of the market and also outlines the challenges faced by the vendors and the market at large, as well as the key trends that are emerging in the market.
TechNavio’s report, the Global Cushing’s Syndrome Therapeutics market 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas, and the EMEA and APAC regions; it also covers the Global BI and Analytics Platform market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market.

[Key Regions]
• Americas
• APAC
• EMEA

[Key Vendors]
• Corcept Therapeutics
• HRA Pharma
• Novartis

[Other Prominent Vendors]
• Aspireo Pharmaceuticals
• Cortendo
• ElexoPharm
• Ipsen
• Isis Pharmaceuticals
• Orphagen Pharmaceuticals
• Samaritan Pharmaceuticals

[Market Driver]
• Presence of Unmet Need
• For a full, detailed list, view our report

[Market Challenge]
• Adverse Effects of Drugs
• For a full, detailed list, view our report

[Market Trend]
• Increase in Awareness
• For a full, detailed list, view our report

[Key Questions Answered in this Report]
• What will the market size be in 2018 and what will the growth rate be?
• What are the key market trends?
• What is driving this market?
• What are the challenges to market growth?
• Who are the key vendors in this market space?
• What are the market opportunities and threats faced by the key vendors?
• What are the strengths and weaknesses of the key vendors?

【資料の目次】

01. Executive Summary

02.List of Abbreviations

03.Scope of the Report
03.1 Market Overview
03.2 Product Offerings

04.Product Profiles
04.1.1 Signifor
04.1.2 Korlym
04.1.3 Ketoconazole HRA

05.Market Research Methodology
05.1 Market Research Process
05.2 Research Methodology

06.Introduction

07.Disease Overview
07.1.1 Understanding the Disease
07.1.2 Etiology and Pathophysiology
07.1.3 Rate of Incidence and Prevalence
07.1.4 Diagnosis of Cushing’s Syndrome
07.1.5 Management of Cushing’s Syndrome
07.1.6 Economic Burden due to Cushing’s Syndrome

08.Market Landscape
08.1 Market Overview
08.2 Market Size and Forecast
08.3 Five Forces Analysis

09.Market Segmentation by Class of Drugs
09.1 Glucocorticoid Receptor Antagonist
09.2 Somatostatin Analog
09.3 Cortisol Synthesis Inhibitor
09.4 Others

10.Market Segmentation by Route of Administration
10.1 Oral
10.2 Parenteral

11.Market Segmentation by Dosage Form
11.1 Solid
11.2 Liquid

12.Geographical Segmentation

13.Buying Criteria

14.Market Growth Drivers

15.Drivers and their Impact

16.Market Challenges

17.Impact of Drivers and Challenges

18.Market Trends

19.Trends and their Impact

20.Vendor Landscape
20.1 Competitive Scenario
20.1.1 Key News
20.1.2 Mergers and Acquisitions
20.2 Market Share Analysis 2014
20.2.1 Novartis
20.2.2 Corcept Therapeutics
20.2.3 HRA Pharma
20.3 Other Prominent Vendors

21.Pipeline Portfolio
21.1 Key Information for the Pipeline Candidates
21.1.1 LCI-699
21.1.2 COR-003
21.1.3 Cabergoline
21.1.4 ISIS-GCCRRx
21.1.5 DG-3173

22.Key Vendor Analysis
22.1 Corcept Therapeutics
22.1.1 Key Facts
22.1.2 Business Overview
22.1.3 Recent Developments
22.1.4 SWOT Analysis
22.2 HRA Pharma
22.2.1 Key Facts
22.2.2 Business Overview
22.2.3 Therapeutic Areas
22.2.4 Business Strategy
22.2.5 Recent Developments
22.2.6 SWOT Analysis
22.3 Novartis
22.3.1 Key Facts
22.3.2 Business Description
22.3.3 Business Segmentation
22.3.4 Revenue by Business Segmentation
22.3.5 Revenue Comparison 2012 and 2013
22.3.6 Sales by Geography
22.3.7 Business Strategy
22.3.8 Key Developments
22.3.9 SWOT Analysis

23.Other Reports in this Series

[List of Exhibits]
Exhibit 1: Market Research Methodology
Exhibit 2: Etiology of Cushing’s Syndrome
Exhibit 3: Diagrammatic Representation of Cortisol Secretion and its Feedback Loop
Exhibit 4: Causes of Cushing’s Syndrome
Exhibit 5: Diagnosis Algorithm of Cushing’s Syndrome
Exhibit 6: Global Overactive Bladder Therapeutics Market 2015-2019 (US$ million)
Exhibit 7: Global Cushing’s Syndrome Therapeutics Market Segmentation by Class of Drugs
Exhibit 8: Global Cushing’s Syndrome Therapeutics Market by Class of Drugs 2014
Exhibit 9: Global Cushing’s Syndrome Therapeutics Market Segmentation by Route of Administration
Exhibit 10: Global Cushing’s Syndrome Therapeutics Market by Route of Administration 2014
Exhibit 11: Global Cushing’s Syndrome Therapeutics Market Segmentation by Dosage Form
Exhibit 12: Global Cushing’s Syndrome Therapeutics Market by Dosage Form 2014
Exhibit 13: Global Overactive Bladder Therapeutics Market by Geographical Segmentation 2014
Exhibit 14: Global Cushing’s Syndrome Therapeutics Market Share Analysis 2014
Exhibit 15: Snapshot of Pipeline Drugs 2014
Exhibit 16: Study Count of Cushing’s Syndrome Clinical Trials
Exhibit 17: Study Count of Cushing’s Syndrome Clinical Trials
Exhibit 18: Novartis AG: Business Segmentation
Exhibit 19: Novartis AG: Revenue by Business Segmentation 2013
Exhibit 20: Novartis AG: Revenue by Business Segmentation 2012 and 2013 (US$ million)
Exhibit 21: Novartis AG: Revenue by Geographical Segmentation 2013
Exhibit 22: HRA Pharma: Therapeutic Areas



【掲載企業】

Corcept Therapeutics , HRA Pharma , Novartis , Aspireo Pharmaceuticals, Cortendo, ElexoPharm, Ipsen, Isis Pharmaceuticals, Orphagen Pharmaceuticals, Samaritan Pharmaceuticals

【資料のキーワード】

クッシング症候群、治療薬、製薬、薬剤、コルチコイド受容体拮抗薬、ソマトスタチン類縁体、コルチゾール合成阻害剤

【調査方法】

一次資料による調査(業界専門家、ベンダー、代理店、顧客等を対象にしたデプスインタビュー調査など)及び二次資料による調査(Technavio独自のプラットフォーム、産業書籍、企業報告書、ニュース記事、アナリストレポート、貿易協会、政府機関発行データなど)

★調査レポート[クッシング症候群(Cushing’s Syndrome)治療薬の世界市場:コルチコイド受容体拮抗薬、ソマトスタチン類縁体、コルチゾール合成阻害剤] (Global Cushing's Syndrome Therapeutics Market 2015-2019 / IRTNTR4695)販売に関する免責事項
[クッシング症候群(Cushing’s Syndrome)治療薬の世界市場:コルチコイド受容体拮抗薬、ソマトスタチン類縁体、コルチゾール合成阻害剤] (Global Cushing's Syndrome Therapeutics Market 2015-2019 / IRTNTR4695)についてEメールでお問い合わせ


◆H&Iグローバルリサーチ株式会社のお客様(例)◆